Fierce Biotech1 min read
saveBoehringer Ingelheim boosts Variant Bio partnership with $250 million for cardiovascular research
read at Fierce Biotech ↗DealPositive
Boehringer Ingelheim announced an expansion of its collaboration with Variant Bio.
The partnership will now include cardiovascular disease research, broadening its original scope.
The deal value has been increased by $250 million, reflecting the broader scope.
The added focus aims to leverage Variant's platform to discover new treatments for heart conditions.
source
This writeup was produced by pharmadog from original reporting by Fierce Biotech.
Original headline: “Boehringer adds $250M to value of Variant pact by expanding into cardiovascular disease”
read at Fierce Biotech ↗368 words · retrieved Sep 23
comments(0)
5-min edit window · permanent after that